HalfLifeDBEvidence before certainty.

2C-B evidence profile

The disposition study linked here was conducted in rats.

Category: psychedelic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

2C-B: evidence and interpretation notes

Why HalfLifeDB does not plot 2C-B

The disposition study linked here was conducted in rats. It is useful for understanding candidate metabolites and research methods, but translating its time course into a human half-life would create precision that the cited evidence does not contain.

2C-B has much thinner public pharmacokinetic literature than long-established medicines, so this entry is intentionally conservative. The cited material includes an animal disposition study and a direct compound record rather than a broad clinical label.

Because the evidence base is limited, source quality matters more than the number itself. Treat the calculator as a way to understand exponential decay when the underlying estimate is uncertain.

What each source contributes

  • Kanamori T et al. Disposition of 2C-B and a metabolite in rats (2008). This preclinical study documents species-specific disposition or assay work and is not translated into a typical human estimate.
  • PubChem: 2C-B. This identity record confirms names and compound identity and does not supply a human half-life.

For 2C-B, the decision to withhold a curve turns on the limits visible in Kanamori T et al. Disposition of 2C-B and a metabolite in rats (2008). This preclinical study documents species-specific disposition or assay work, but it is not translated into a typical human estimate.

What evidence would change the page

For 2C-B, stronger evidence means more than detection or biological activity: it means a clearly reported human elimination estimate tied to one analyte and route. That numerical bridge is absent from Kanamori T et al. Disposition of 2C-B and a metabolite in rats (2008).

InterpretationCategory context and evidence limits

psychedelic context

Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.

  • The curve does not predict psychological effects or functional safety.
  • Metabolites and downstream receptor activity are not separately modeled.
  • Published estimates may come from small or specialized study populations.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Research abstract Kanamori T et al. Disposition of 2C-B and a metabolite in rats (2008).
    Rat disposition study; included because public human pharmacokinetic evidence is limited.
  2. Identity record PubChem Compound Summary: 2C-B.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.